Back to Search Start Over

AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper.

Authors :
Bergmann C
Poli A
Agache I
Bianchini R
Bax HJ
Castells M
Crescioli S
Dombrowicz D
Ferastraoaru D
Fiebiger E
Gould HJ
Hartmann K
Izquierdo E
Jordakieva G
Josephs DH
Jutel M
Levi-Schaffer F
de Las Vecillas L
Lotze MT
Osborn G
Pascal M
Redegeld F
Rosenstreich D
Roth-Walter F
Schmidt-Weber C
Shamji M
Steveling EH
Turner MC
Untersmayr E
Jensen-Jarolim E
Karagiannis SN
Source :
Allergy [Allergy] 2022 Sep; Vol. 77 (9), pp. 2594-2617. Date of Electronic Publication: 2022 Mar 14.
Publication Year :
2022

Abstract

The immune system interacts with many nominal 'danger' signals, endogenous danger-associated (DAMP), exogenous pathogen (PAMP) and allergen (AAMP)-associated molecular patterns. The immune context under which these are received can promote or prevent immune activating or inflammatory mechanisms and may orchestrate diverse immune responses in allergy and cancer. Each can act either by favouring a respective pathology or by supporting the immune response to confer protective effects, depending on acuity or chronicity. In this Position Paper under the collective term danger signals or DAMPs, PAMPs and AAMPs, we consider their diverse roles in allergy and cancer and the connection between these in AllergoOncology. We focus on their interactions with different immune cells of the innate and adaptive immune system and how these promote immune responses with juxtaposing clinical outcomes in allergy and cancer. While danger signals present potential targets to overcome inflammatory responses in allergy, these may be reconsidered in relation to a history of allergy, chronic inflammation and autoimmunity linked to the risk of developing cancer, and with regard to clinical responses to anti-cancer immune and targeted therapies. Cross-disciplinary insights in AllergoOncology derived from dissecting clinical phenotypes of common danger signal pathways may improve allergy and cancer clinical outcomes.<br /> (© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Details

Language :
English
ISSN :
1398-9995
Volume :
77
Issue :
9
Database :
MEDLINE
Journal :
Allergy
Publication Type :
Academic Journal
Accession number :
35152450
Full Text :
https://doi.org/10.1111/all.15255